<DOC>
	<DOCNO>NCT02601820</DOCNO>
	<brief_summary>The PROP UP research study fund The Patient Centered Outcomes Research Institute ( PCORI ) . PROP UP multi-centered prospective observational study evaluate all-oral treatment regimen HCV regard several patient-reported outcome ( PROs ) HCV-associated symptom , treatment side effect , medication adherence , pocket cost , comorbid condition , long-term benefit cure harm treatment compare PROs different treatment regimen , treatment duration , patient subgroup . Participants recruit 9 U.S. liver center . Approximately 1920 patient HCV infection prescribe regimen contain Harvoni® , Viekera Pak® , Zepatier® , DAC/SOF SOF/VEL chronic HCV recruit approximately 1600 patient approve begin HCV treatment enrol longitudinal study . PRO survey evaluate , HCV treatment . PROP UP collaborative effort behavioral biomedical researcher , patient engagement group patient advocacy organization .</brief_summary>
	<brief_title>The Patient-Reported Outcomes Project HCV-TARGET</brief_title>
	<detailed_description>Newer , effective all-oral regimen hepatitis C viral ( HCV ) infection available . However available data industry-sponsored trial provide information patient need , data represent broad spectrum patient treat real-world practice . Trials also exclude disadvantaged subgroup , focus short-term efficacy clinician-rated adverse event , rarely obtain patient 's perspective , investigate longer-term harm treatment benefit viral cure . Given informational gap , patient-centered outcome research ( PCOR ) treatment harm benefit matter patient , need . PROP UP fund The Patient Centered Outcomes Research Institute ( PCORI ) . PROP UP multi-centered prospective observational study evaluate 5 newly approve DAA treatment regimens HCV regard several patient-reported outcome ( PROs ) HCV-associated symptom , treatment side effect , medication adherence , pocket cost , comorbid condition , long-term benefit cure harm treatment compare PROs different treatment regimen , treatment duration , patient subgroup . PROP UP collaborative effort researcher , patient engagement group , patient advocacy organization . Nine U.S. liver center collaborate PROP UP . Approximately 1920 patient HCV infection prescribe regimen contain Harvoni® , Viekera Pak® , Zepatier® , DAC/SOF SOF/VEL chronic HCV consent complete baseline PRO survey . Approximately 1600 patient approve begin HCV treatment enrol longitudinal study . Participants complete several PRO survey 5 assessment period study : baseline , treatment week 4 , end treatment , 3 month post-treatment , 12 month post-treatment . PRO survey data collect via 3 option : patient home-based computer , tablet , smartphone ; phone-administered survey centralize call enter ; regular clinic visit . Analysis PROs collect longitudinally , treatment HCV allow investigator answer variety question important patient clinician . Specifically , investigator evaluate : ( ) prevalence pre-existing baseline symptom associate HCV ; ( b ) development new onset treatment side effect exacerbation pre-existing symptom HCV treatment ; ( c ) medication adherence pocket cost associate treatment ; ( ) change HCV-associated symptom functional status patient cure ; ( e ) long-term patient-reported harm associate treatment long-term benefit associate viral cure .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Diagnosed HCV genotype 16 Englishspeaking Age 21 old Medically clear prescribed one follow DAA regimen : sofosbuvir/ledipasvir ( Harvoni® ) without ribavirin ombitasvir/paritaprevir/ritonavir dasabuvir ( Viekera Pak® ) , VPK ) without ribavirin elbasvir/grazoprevir ( Zepatier® ) without ribavirin daclatasvir/sofosbuvir , without ribavirin ( DAC/SOF ) sofosbuvir/velpatasvir ( SOF/VEL ) Inability provide write informed consent Currently participate pharmaceuticalsponsored drug trial hepatitis C treatment Major cognitive mental impairment Unable read speak English Unwilling unable complete survey questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>patient-reported outcome</keyword>
	<keyword>observational</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic Liver Disease</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Liver</keyword>
	<keyword>Infectious Disease</keyword>
	<keyword>Hep C</keyword>
	<keyword>HepC</keyword>
	<keyword>PROs</keyword>
</DOC>